News

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology.

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.

Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.

Investors need to pay close attention to HALO stock based on the movements in the options market lately.

Halozyme Therapeutics stock snapshot after recent performance Halozyme Therapeutics (HALO) has drawn investor attention after a mixed recent run, with the stock up over the past month but down over the past 3 months, prompting a closer look at its fundamentals. See our latest analysis for Halozyme Therapeutics. Recent trading has been mixed, with a 30 day share price return of 4.53% but a 90 day share price return that is down 2.90%. In contrast, the 1 year total shareholder return of 25.27%...

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Halozyme Therapeutics (NASDAQ:HALO) and the rest of the therapeutics stocks fared in Q1.

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 42.2% year on year to $376.7 million. The company expects the full year’s revenue to be around $1.76 billion, close to analysts’ estimates. Its non-GAAP profit of $1.60 per share was 5.3% above analysts’ consensus estimates.

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what to expect.

Companies In The News Are: SPG, HIMS, NOVT, HALO.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on May 7 that the company entered into a global collaboration and license agreement with GSK, under which GSK has licensed Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of […]

Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu

Halozyme Therapeutics Inc (HALO) reports a 42% revenue surge, unveils a $1 billion share buyback, and outlines ambitious growth plans for 2026.

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 42.2% year on year to $376.7 million. The company expects the full year’s revenue to be around $1.76 billion, close to analysts’ estimates. Its non-GAAP profit of $1.60 per share was 5.3% above analysts’ consensus estimates.

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in. TheFly reported on April 29 that H.C. Wainwright increased its price objective for HALO to $95 from $90 and reiterated its Buy recommendation on the […]

Halozyme Therapeutics (HALO) is back on investors’ radar after recent share price swings, with the stock roughly flat over the month but showing a near 20% decline over the past 3 months. See our latest analysis for Halozyme Therapeutics. At a share price of $65.19, Halozyme’s recent 90 day share price return of roughly a 20% decline contrasts with a far stronger 3 year total shareholder return of about 98%. This suggests longer term holders have still seen substantial gains even as recent...

ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]

Halozyme Therapeutics recently announced that Darren Snellgrove, a veteran finance leader with more than 30 years of biopharma experience including senior roles at Johnson & Johnson, will become its Chief Financial Officer on June 8, 2026, overseeing financial operations, capital allocation, corporate development, and investor relations. Snellgrove’s background combining investor relations leadership and oversight of a Johnson & Johnson pharmaceuticals business generating over...

Halozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.